Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-07-11; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting2023-08-30